TABLE 3.
Inhibition of vaccinia virus yield by SOCS1-KIR and Tkipa
| Treatment | Virus yield (105)
|
% of control
|
||
|---|---|---|---|---|
| Intracellular | Extracellular | Extracellular | Intracellular | |
| None | 390 ± 29.0 | 3.3 ± 0.2 | ||
| SOCS1-KIR | 40 ± 3.0 | 0.57 ± 0.03 | 10.2 | 17 |
| SOCS1-KIR2A | 354 ± 30.0 | 2.9 ± 0.01 | 90.7 | 88 |
| Tkip | 35 ± 2.5 | 0.62 ± 0.04 | 8.9 | 18 |
| Tkip2A | 345 ± 30 | 2.7 ± 0.2 | 81 | 82 |
| IFN-γ(95-132) | 45 ± 5.0 | 0.45 ± 0.04 | 11.5 | 13 |
a
A single-step assay of vaccinia virus yield was performed on confluent BSC-40 cells infected with virus at an MOI of 5. The peak virus yield after 24 h of infection, as shown in Fig. 6, was used for calculations. Peptides were used at a final concentration of 50 μM. The experiment was carried out in triplicate and repeated twice with similar results. There was a statistically significant difference between the lipo-SOCS1-KIR and lipo-Tkip treatments versus no treatment (P < 0.001), while the results obtained with the mutant forms were not significantly different by the Mann-Whitney signed-rank test.